Journal of Clinical Endocrinology & Metabolism, Vol 81, 2976-2979, Copyright © 1996 by Endocrine Society

ARTICLES

Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease

M Salvi, G Girasole, M Pedrazzoni, M Passeri, N Giuliani, R Minelli, LE Braverman and E Roti
Centro per lo Studio, Prevenzione, Diagnosi e Cura delle Tireopatie, Universita degli Studi di Parma, Italy.

Increased serum interleukin-6 (IL-6) concentrations have been reported in patients with thyroid destructive processes. In the present study we measured IL-6 and soluble IL-6 receptor (sIL-6R) concentrations in the serum of normal subjects and patients with Graves' disease using a high sensitivity sandwich enzyme-linked immunoassay. We found increased serum IL-6 and sIL-6R concentrations (69.3 fmol/L, and 964 pmol/L, respectively) in 49 hyperthyroid patients with Graves' disease (GD) compared to those in controls [55.8 fmol/L (P = 0.019) and 772 pmol/L (P = 0.007), respectively]. In 31 newly diagnosed GD patients, serum concentrations of IL-6 and sIL-6R during the hyperthyroid phase were elevated, and after therapy with methimazole only, serum sIL-6R concentrations returned to normal (940 vs. 726 pmol/L; P < 0.001) but serum IL-6 did not. Serum sIL-6R concentrations (mean +/- 2 SD) were higher in GD patients with active inflammatory thyroid-associated ophthalmopathy than those in patients with inactive or absent thyroid- associated ophthalmopathy (P < 0.05). In conclusion, we have demonstrated activation of the IL-6 system in GD and, for the first time, have measured and found increased serum sIL-6R concentrations in hyperthyroid GD patients.

This article has been cited by other articles:

				A. Antonelli, P. Fallahi, M. Rotondi, S. M. Ferrari, P. Romagnani, M. Grosso, E. Ferrannini, and M. Serio Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur. J. Endocrinol., May 1, 2006; 154(5): 651 - 658. [Abstract] [Full Text] [PDF]

				A. L. D. Riis, T. K. Hansen, S. Thiel, C. H. Gravholt, S. Gjedde, L. C. Gormsen, J. O. L. Jorgensen, J. Weeke, and N. Moller Thyroid hormone increases mannan-binding lectin levels Eur. J. Endocrinol., November 1, 2005; 153(5): 643 - 649. [Abstract] [Full Text] [PDF]

				B. Chen, S. Tsui, and T. J. Smith IL-1{beta} Induces IL-6 Expression in Human Orbital Fibroblasts: Identification of an Anatomic-Site Specific Phenotypic Attribute Relevant to Thyroid-Associated Ophthalmopathy J. Immunol., July 15, 2005; 175(2): 1310 - 1319. [Abstract] [Full Text] [PDF]

				D. S. Cooper Antithyroid Drugs N. Engl. J. Med., March 3, 2005; 352(9): 905 - 917. [Full Text] [PDF]

				B. S. Prabhakar, R. S. Bahn, and T. J. Smith Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy Endocr. Rev., December 1, 2003; 24(6): 802 - 835. [Abstract] [Full Text] [PDF]

				A. F. Muller, H. A. Drexhage, and A. Berghout Postpartum Thyroiditis and Autoimmune Thyroiditis in Women of Childbearing Age: Recent Insights and Consequences for Antenatal and Postnatal Care Endocr. Rev., October 1, 2001; 22(5): 605 - 630. [Abstract] [Full Text] [PDF]

				S. A. JONES, S. HORIUCHI, N. TOPLEY, N. YAMAMOTO, and G. M. FULLER The soluble interleukin 6 receptor: mechanisms of production and implications in disease FASEB J, January 1, 2001; 15(1): 43 - 58. [Abstract] [Full Text] [PDF]

				A. Siddiqi, J. P. Monson, D. F. Wood, G. M. Besser, and J. M. Burrin Serum Cytokines in Thyrotoxicosis J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 435 - 439. [Abstract] [Full Text]

				G. D. Sempowski, J. Rozenblit, T. J. Smith, and R. P. Phipps Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production Am J Physiol Cell Physiol, March 1, 1998; 274(3): C707 - C714. [Abstract] [Full Text] [PDF]

				T. J. Smith, G. D. Sempowski, C. S. Berenson, H. J. Cao, H.-S. Wang, and R. P. Phipps Human Thyroid Fibroblasts Exhibit a Distinctive Phenotype in Culture: Characteristic Ganglioside Profile and Functional CD40 Expression Endocrinology, December 1, 1997; 138(12): 5576 - 5588. [Abstract] [Full Text] [PDF]

				I. Celik More Than IL-6 in Graves' Disease? J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1307 - 1307. [Full Text] [PDF]

				M. Salvi, G. Girasole, M. Pedrazzoni, M. Passeri, N. Giuliani, R. Minelli, and E. Roti More Than IL-6 in Graves' Disease?--Authors' Response J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1307a - 1307. [Full Text]